by Paul | 20th March 2024 | News
-Phase 2 OK-101 efficacy data to be released March 22, 2024- London and New York, NY, March 20, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye...
by Paul | 9th February 2024 | News
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized,...
by Paul | 31st January 2024 | News
London and New York, NY, January 31, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic... by Paul | 8th January 2024 | News
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing Statistically significant improvement was observed in both a “sign” (total conjunctival staining) and two “symptoms”... by Paul | 5th January 2024 | News
London and New York, NY, January 5, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal...
